PALI
$1.99
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases.
Recent News
Palisade Bio Details PALI-2108 UC, Crohn’s Plans and Cash Runway Into 2029 at Oppenheimer Conference
Palisade Bio (NASDAQ:PALI) executives outlined the company’s strategic pivot, lead development priorities, and financing position during a fireside chat at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference. Company background and strategic pivot Chief Executive Officer J.D. Finley said
Here Are Monday’s Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More
Pre-Market Stock Futures: The futures are trading lower as we begin the final trading week of 2025, albeit a holiday-shortened one once again. The major indices all finished the session modestly lower on Friday, with the venerable S&P 500 taking early bows as it hit a fresh all-time high, joining the Dow Jones Industrial Average ... Here Are Monday’s Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More
Palisade Bio (PALI) Soars 5% Ahead of Clinical Trial Results
We recently published 10 Stocks Lighting Up Market Ahead of Christmas. Palisade Bio Inc. (NASDAQ:PALI) is one of the best performers on Wednesday. Palisade extended its winning streak to a fourth straight day on Wednesday, jumping 5.26 percent to close at $2.20 apiece as investors loaded portfolios ahead of the results of its clinical trial […]
Palisade Bio (PALI) Upgraded to Buy: Here's What You Should Know
Palisade Bio (PALI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Individual investors are Palisade Bio, Inc.'s (NASDAQ:PALI) biggest owners and were rewarded after market cap rose by US$70m last week
Key Insights Palisade Bio's significant individual investors ownership suggests that the key decisions are influenced...